Nabilone
Top: (R,R)-(−)-nabilone, Center: (S,S)-(+)-nabilone, Bottom: Space-filling model of (R,R)-(−)-nabilone | |
| Clinical data | |
|---|---|
| Trade names | Cesamet, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607048 |
| Routes of administration | By mouth |
| Drug class | Cannabinoid |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 20% after first-pass by the liver |
| Protein binding | similar to THC (±97%) |
| Elimination half-life | 2 hours, with metabolites around 35 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.164.824 |
| Chemical and physical data | |
| Formula | C24H36O3 |
| Molar mass | 372.549 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Nabilone, sold under the brand name Cesamet among others, is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It mimics tetrahydrocannabinol (THC), the primary psychoactive compound found naturally occurring in Cannabis.
The Food and Drug Administration (FDA) in the United States has indicated nabilone for chemotherapy-induced nausea/vomiting. In other countries, such as Canada, it is widely used as an adjunct therapy for chronic pain management. Numerous trials and case studies have demonstrated modest effectiveness for relieving fibromyalgia and multiple sclerosis.